Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc Receives Approval for Manufacturing and Marketing of "Cimzia"


Tuesday, 25 Dec 2012 01:00am EST 

Astellas Pharma Inc announced that it has obtained approval for manufacturing and marketing of Cimzia 200mg Syringe for S.C. Injection, which is also known as Certolizumab Pegol (Genetical Recombination), and used as a treatment for rheumatoid arthritis, in Japan. 

Company Quote

1399.5
-12.0 -0.85%
24 Jul 2014